<p>即使在未來，藍籌股仍然是所有可用股票中最可靠的之一。這是因為它們屬於具有穩健財務和增長潛力的企業和公司。對於尋求進行低風險、穩定投資並在長期內獲得巨大回報的投資者來説，它們也是完美的選擇。</p>
<p>儘管如此，許多藍籌股市值較高，投資於它們可能需要大量資本，而大多數投資者要麼沒有這麼多資本，要麼不願意投入。這樣的投資者應該轉向未來的藍籌股，這些股票通常更便宜，具有相同的優質特質。</p>
<p>本文重點介紹了三隻未來藍籌股，可能在今年下半年及以後帶來巨大的股息。</p>
<h2>沃爾瑪（WMT）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>圖片來源：Jonathan Weiss / Shutterstock.com</p>
<p><strong>沃爾瑪</strong>（紐約證券交易所：<strong>WMT</strong>）是一家美國零售巨頭，擁有遍佈全國的大賣場、折扣百貨商店和雜貨店。在零售業中，有幾家公司的市場份額比沃爾瑪更大，尤其是在美國市場，沃爾瑪控制着大部分市場份額。</p>
<p>儘管在美國零售市場佔據牢固地位，沃爾瑪表現出繼續增長和改進產品和服務範圍的承諾。在過去幾年中，它推出了多項擴大業務的舉措，例如推出訂閲服務 Walmart+。還有傳言稱其有意收購知名電視製造商 Vizio。</p>
<p>沃爾瑪增長潛力的另一個例子是其持續的擴張努力。該公司預計在未來五年內將在美國開設或改建 100 多家門店。這些門店可能會繼續保持沃爾瑪的傳統，如大型促銷活動、價格優惠和折扣。</p>
<p>在財務方面，沃爾瑪又度過了一個高盈利的一年。根據其最新季度報告，該公司的綜合收入增長了 6%，創造了令人矚目的 1615 億美元。</p>
<p>此外，其電子商務和廣告業務也實現了顯著增長，分別增長了 21% 和 24%。</p>
<h2>摩根大通（JEF）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>圖片來源：T. Schneider/ShutterStock.com</p>
<p><strong>摩根大通金融集團</strong>（紐約證券交易所：<strong>JEF</strong>）是一家總部位於紐約的獨立投資銀行和金融服務提供商。它是投資銀行和資本市場領域的全球領導者，在投資銀行、全球研究與策略、另類資產管理、財富管理、股票和固定收益等各個領域擁有深厚的專業知識。</p>
<p>摩根大通金融集團是盈利的典範。自 1983 年上市以來，該銀行的回報率是標普 500 指數的兩倍，100 美元的投資現在價值 12775 美元。</p>
<p>此外，像大多數藍籌公司一樣，摩根大通金融集團以支付和增長股息而聞名。它的股息不僅每年產生 2.8% 的收益，而且在過去五年中以 22% 的複合年增長率增加了股息，使其成為市場上收益最高的股票之一。</p>
<p>從銀行的財務狀況來看，根據其最新季度報告，摩根大通金融集團度過了一個出色的一年，在收入和利潤等關鍵指標上取得了令人矚目的成績。它創造了 16.6 億美元的淨收入，並將季度現金股息提高了 16.7%。</p>
<h2>禮來（LLY）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>圖片來源：shutterstock.com/Michael Vi</p>
<p><strong>禮來</strong>（紐約證券交易所：<strong>LLY</strong>）是一家總部位於印第安納波利斯的製藥公司。它以生產治療癌症、糖尿病、骨骼肌肉關節、心血管、內分泌、免疫學、神經科學和肥胖症等領域的藥物而聞名。其藥物也在全球 100 多個國家提供。</p>
<p>由於其在各種治療領域的多樣化業務和產品，禮來成為一個具有高潛力的藍籌股。特別是在糖尿病和肥胖控制領域，得益於其旗艦糖尿病治療藥物 Trulicity 的成功。</p>
<p>根據其最新季度報告，該藥物僅在今年第一季度就產生了 15 億美元的收入。報告還顯示，公司最新的糖尿病藥物 Mounjaro 在同一時期也表現良好，產生了 18 億美元的收入。</p>
<p>另一種類似於 Mounjaro 但也治療減肥的藥物 Zepbound，在今年第一季度也產生了 5.17 億美元的收入。</p>
<p>以 7300 億美元的市值，禮來是製藥行業中最盈利豐厚的公司之一，也是最有價值的醫療保健股票之一。</p>
<p><em>在本文發佈日期，Joel Lim 對本文提及的證券沒有（直接或間接）任何持倉。本文中表達的觀點屬於作者個人，遵守 InvestorPlace.com 的發佈準則。</em></p>
<p><em>在本文發佈日期，負責編輯對本文提及的證券沒有（直接或間接）任何持倉。</em></p>
<p>Joel Lim 是 InvestorPlace.com 的撰稿人，也是一名金融內容承包商，為 LTSE 和 Realtor 等多家公司以及 Business Insider、Yahoo Finance、Mises Institution 和 Foundation for Economic Education 等金融出版物創作內容。</p>
<p>消費者自由裁量權、金融、醫療保健、零售</p>
<p>藍籌股</p>

沃爾瑪

摯文集團

禮來

<p>沃爾瑪、摯文集團和禮來是三隻未來有潛力獲得高回報的藍籌股。沃爾瑪不斷擴大和改進其產品和服務，而摯文集團具有良好的盈利記錄和股息增長。禮來以其多樣化的製藥產品而聞名，特別是在糖尿病和肥胖控制領域。這些股票為投資者提供了穩定且低風險的投資機會，同時具有可觀的股息潛力</p>

<p>Even in the future, blue-chip stocks will be among the most reliable of all the available stocks. That’s because they belong to businesses and companies with solid financials and growth potential. They are also the perfect options for investors looking to make low-risk, stable investments that will yield massive returns over the long run.</p>
<div class="lb-trans"><p>即使在未來，藍籌股仍然是所有可用股票中最可靠的之一。這是因為它們屬於具有穩健財務和增長潛力的企業和公司。對於尋求進行低風險、穩定投資並在長期內獲得巨大回報的投資者來説，它們也是完美的選擇。</p>
</div><p>While that is the case, many blue-chip stocks are high-cap, and investing in them may take a lot of capital that most investors simply do not have or are unwilling to fork out. Such investors should look towards future blue-chip stocks, which are often cheaper and possess the same qualities.</p>
<div class="lb-trans"><p>儘管如此，許多藍籌股市值較高，投資於它們可能需要大量資本，而大多數投資者要麼沒有這麼多資本，要麼不願意投入。這樣的投資者應該轉向未來的藍籌股，這些股票通常更便宜，具有相同的優質特質。</p>
</div><p>This article highlights three future blue-chip stocks that could yield huge dividends in the second half of the year and beyond.</p>
<div class="lb-trans"><p>本文重點介紹了三隻未來藍籌股，可能在今年下半年及以後帶來巨大的股息。</p>
</div><h2>Walmart (WMT)</h2>
<div class="lb-trans"><h2>沃爾瑪（WMT）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Jonathan Weiss / Shutterstock.com</p>
<div class="lb-trans"><p>圖片來源：Jonathan Weiss / Shutterstock.com</p>
</div><p><strong>Walmart</strong> (NYSE: <strong>WMT</strong>) is an American retail giant with a chain of hypermarkets, discount department stores and grocery stores scattered across the country. There are a handful of companies in the retail business with a more substantial presence than Walmart, especially in the American market, where it controls most of the market share.</p>
<div class="lb-trans"><p><strong>沃爾瑪</strong>（紐約證券交易所：<strong>WMT</strong>）是一家美國零售巨頭，擁有遍佈全國的大賣場、折扣百貨商店和雜貨店。在零售業中，有幾家公司的市場份額比沃爾瑪更大，尤其是在美國市場，沃爾瑪控制着大部分市場份額。</p>
</div><p>Despite its firm grip on the American retail scene, Walmart has shown a commitment to continuing to grow and improve the range of its products and services. Over the last few years, it has launched several efforts to expand its business, such as the launch of its subscription service, Walmart+. There is also talk of acquiring popular television maker Vizio.</p>
<div class="lb-trans"><p>儘管在美國零售市場佔據牢固地位，沃爾瑪表現出繼續增長和改進產品和服務範圍的承諾。在過去幾年中，它推出了多項擴大業務的舉措，例如推出訂閲服務 Walmart+。還有傳言稱其有意收購知名電視製造商 Vizio。</p>
</div><p>Another example of Walmart’s growth potential is its consistent expansion efforts. The company anticipates opening or converting over 100 stores across the US in the next five years. These stores will likely continue popular Walmart traditions, such as massive sales events, price slashes and discounts.</p>
<div class="lb-trans"><p>沃爾瑪增長潛力的另一個例子是其持續的擴張努力。該公司預計在未來五年內將在美國開設或改建 100 多家門店。這些門店可能會繼續保持沃爾瑪的傳統，如大型促銷活動、價格優惠和折扣。</p>
</div><p>On the financial front, Walmart is enjoying yet another year of high profitability. According to its latest quarterly report, the company saw a 6% increase in its consolidated revenue, generating an impressive $161.5 billion.</p>
<div class="lb-trans"><p>在財務方面，沃爾瑪又度過了一個高盈利的一年。根據其最新季度報告，該公司的綜合收入增長了 6%，創造了令人矚目的 1615 億美元。</p>
</div><p>Furthermore, its e-commerce and advertising business also grew significantly, increasing by 21% and 24%, respectively.</p>
<div class="lb-trans"><p>此外，其電子商務和廣告業務也實現了顯著增長，分別增長了 21% 和 24%。</p>
</div><h2>Jefferies Financial Group (JEF)</h2>
<div class="lb-trans"><h2>摩根大通（JEF）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: T. Schneider/ShutterStock.com</p>
<div class="lb-trans"><p>圖片來源：T. Schneider/ShutterStock.com</p>
</div><p><strong>Jefferies Financial Group</strong>(NYSE: <strong>JEF</strong>) is an independent investment bank and financial services provider based in New York, New York. It is a global leader in the investment banking and capital markets scene and boasts deep expertise in various sectors, such as investment banking, global research and strategy, alternative asset management, wealth management, equities, and fixed income.</p>
<div class="lb-trans"><p><strong>摩根大通金融集團</strong>（紐約證券交易所：<strong>JEF</strong>）是一家總部位於紐約的獨立投資銀行和金融服務提供商。它是投資銀行和資本市場領域的全球領導者，在投資銀行、全球研究與策略、另類資產管理、財富管理、股票和固定收益等各個領域擁有深厚的專業知識。</p>
</div><p>Jefferies Financial Group is a beacon of profitability. Since going public in 1983, the bank has doubled the returns of the S&amp;P 500, with $100 invested, then being $12,775 now.</p>
<div class="lb-trans"><p>摩根大通金融集團是盈利的典範。自 1983 年上市以來，該銀行的回報率是標普 500 指數的兩倍，100 美元的投資現在價值 12775 美元。</p>
</div><p>Furthermore, like most blue-chip companies, Jefferies Financial Group is well known for paying and growing its dividend. Not only do its dividends yield 2.8% a year, but it has increased the payout at a compounded annual growth rate of 22% in the last five years, making it one of the highest-yielding stocks on the market.</p>
<div class="lb-trans"><p>此外，像大多數藍籌公司一樣，摩根大通金融集團以支付和增長股息而聞名。它的股息不僅每年產生 2.8% 的收益，而且在過去五年中以 22% 的複合年增長率增加了股息，使其成為市場上收益最高的股票之一。</p>
</div><p>A look at the bank’s finances paints the whole picture. According to its latest quarterly report, Jefferies Financial Group has enjoyed a great year, generating impressive numbers across key metrics like revenue and income. It generated a net revenue of $1.66 billion and increased its quarterly cash dividend by 16.7%.</p>
<div class="lb-trans"><p>從銀行的財務狀況來看，根據其最新季度報告，摩根大通金融集團度過了一個出色的一年，在收入和利潤等關鍵指標上取得了令人矚目的成績。它創造了 16.6 億美元的淨收入，並將季度現金股息提高了 16.7%。</p>
</div><h2>Eli Lilly (LLY)</h2>
<div class="lb-trans"><h2>禮來（LLY）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: shutterstock.com/Michael Vi</p>
<div class="lb-trans"><p>圖片來源：shutterstock.com/Michael Vi</p>
</div><p><strong>Eli Lilly</strong>(NYSE:<strong>LLY</strong>) is a pharmaceutical company based in Indianapolis, Indiana. It is notable for producing medicine for treatments in areas such as cancer, diabetes, bone muscle joint, cardiovascular, endocrine, immunology, neuroscience and obesity. Its drugs are also available in over 100 countries across the globe.</p>
<div class="lb-trans"><p><strong>禮來</strong>（紐約證券交易所：<strong>LLY</strong>）是一家總部位於印第安納波利斯的製藥公司。它以生產治療癌症、糖尿病、骨骼肌肉關節、心血管、內分泌、免疫學、神經科學和肥胖症等領域的藥物而聞名。其藥物也在全球 100 多個國家提供。</p>
</div><p>Thanks to its diverse business and offerings across various therapeutic areas, Eli Lilly emerges as a blue-chip stock with high potential. It is especially bullish in the diabetes and obesity control sector thanks to the success of its flagship diabetes treatment, Trulicity.</p>
<div class="lb-trans"><p>由於其在各種治療領域的多樣化業務和產品，禮來成為一個具有高潛力的藍籌股。特別是在糖尿病和肥胖控制領域，得益於其旗艦糖尿病治療藥物 Trulicity 的成功。</p>
</div><p>According to its latest quarterly report, the drug generated $1.5 billion in revenue in the first quarter of the year only. The report also indicates that the company’s newest diabetes drug, Mounjaro, is also performing well in the market, generating $1.8 billion in revenue in the same period.</p>
<div class="lb-trans"><p>根據其最新季度報告，該藥物僅在今年第一季度就產生了 15 億美元的收入。報告還顯示，公司最新的糖尿病藥物 Mounjaro 在同一時期也表現良好，產生了 18 億美元的收入。</p>
</div><p>Another treatment, Zepbound, which is similar to Mounjaro but also treats weight loss, generated $517 million in the first quarter of the year as well.</p>
<div class="lb-trans"><p>另一種類似於 Mounjaro 但也治療減肥的藥物 Zepbound，在今年第一季度也產生了 5.17 億美元的收入。</p>
</div><p>With a market cap of $730 billion, Eli Lilly is one of the most profitable companies in the pharmaceutical industry and one of the most valuable healthcare stocks.</p>
<div class="lb-trans"><p>以 7300 億美元的市值，禮來是製藥行業中最盈利豐厚的公司之一，也是最有價值的醫療保健股票之一。</p>
</div><p><em>On the date of publication, Joel Lim did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.</em></p>
<div class="lb-trans"><p><em>在本文發佈日期，Joel Lim 對本文提及的證券沒有（直接或間接）任何持倉。本文中表達的觀點屬於作者個人，遵守 InvestorPlace.com 的發佈準則。</em></p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or</em></p>
<p><em>indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p><em>在本文發佈日期，負責編輯對本文提及的證券沒有（直接或間接）任何持倉。</em></p>
</div><p>Joel Lim is a contributor at InvestorPlace.com and a finance content contractor who creates content for several companies like LTSE and Realtor, along with financial publications, including Business Insider, Yahoo Finance, Mises Institution and Foundation for Economic Education.</p>
<div class="lb-trans"><p>Joel Lim 是 InvestorPlace.com 的撰稿人，也是一名金融內容承包商，為 LTSE 和 Realtor 等多家公司以及 Business Insider、Yahoo Finance、Mises Institution 和 Foundation for Economic Education 等金融出版物創作內容。</p>
</div><p>Consumer Discretionary, Financial, Healthcare, Retail</p>
<div class="lb-trans"><p>消費者自由裁量權、金融、醫療保健、零售</p>
</div><p>Blue-Chip Stocks</p>
<div class="lb-trans"><p>藍籌股</p>
</div>

3 Future Blue-Chip Stocks That Could Make You Rich

- 藍籌股將來仍將是所有可用股票中最可靠的之一，因為它們屬於財務穩健且具有增長潛力的企業和公司。
- 即使如此，許多藍籌股市值較高，投資可能需要大量資本，而大多數投資者可能沒有或不願意投入。這些投資者應該關注未來的藍籌股，通常價格更便宜且具有相同的品質。
- 本文重點介紹了可能在下半年及以後獲得鉅額股息的三隻未來藍籌股：沃爾瑪（WMT）、Jefferies Financial Group（JEF）和 Eli Lilly（LLY）。

3 只未來可能讓你致富的藍籌股